DeepMed Research

INO-3112

Generic Name: INO-3112

Clinical Trials

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Phase 2

Withdrawn

Conditions: Oropharynx Cancer
HPV-Related Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions: Drug: MEDI0457
Drug: Durvalumab

First Posted Date: 2019-06-28

Last Posted Date: 2022-07-29

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT04001413

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Mount Sinai School of Medicine, The Tisch Cancer Institute, New York, New York, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

and more 1 locations

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer
Human Papilloma Virus

Interventions: Drug: MEDI0457
Device: CELLECTRA®5P device
Drug: Durvalumab

First Posted Date: 2017-05-22

Last Posted Date: 2022-08-25

Lead Sponsor: MedImmune LLC

Target Recruit Count: 35

Registration Number: NCT03162224

Locations: 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy